We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+6.23%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$19.4M
Cap. Flow
+$5.38M
Cap. Flow %
4.06%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$37.3M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$32M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Communication Services 1.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.5B
$48.1M 36.34%
2,279,788
-1,300,000
-36% -$32M
COGT icon
2
Cogent Biosciences
COGT
$6.64B
$37.3M 28.23%
+840,384
New +$37.3M
SYBX
3
DELISTED
Synlogic
SYBX
$24.9M 18.8%
176,798
– –
SPRO icon
4
Spero Therapeutics
SPRO
$66.6M
$19.6M 14.83%
1,376,968
– –
SNAP icon
5
Snap
SNAP
$8.48B
$2.38M 1.8%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q1 2018 Portfolio in Review

As of Q1 2018, Atlas Venture Associates IX held 5 positions worth $132M, up 17% from $113M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX deployed $5.38M of net new capital in Q1 2018, opening 1 new position. Its largest new stake was Cogent Biosciences: 840,384 shares worth $37.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Intellia Therapeutics, an estimated $32M trimmed.

  • Atlas Venture Associates IX's largest Q1 2018 buy was Cogent Biosciences: 840,384 shares worth $37.3M.
  • Atlas Venture Associates IX's biggest Q1 2018 reduction was Intellia Therapeutics, cutting an estimated $32M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $132M portfolio in Q1 2018.
  • Atlas Venture Associates IX opened 1 new position and closed 0 in Q1 2018.
  • Atlas Venture Associates IX's portfolio value rose 17% quarter-over-quarter to $132M.

Based on Atlas Venture Associates IX's 13F filing for Q1 2018, filed 8 May 2018.